PuraPharm Corporation Limited provided earnings guidance for the six months ended June 30, 2020. The board of directors of the Company inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2020 and other information currently available to the Board, it is expected that the Group's will record a net profit of approximately HKD 10 million for 2020 Interim Period, as compared with the net loss of HKD 45.2 million during the corresponding period in 2019. Such net profit is mainly attributable to a significant increase in non-recurring People's Republic of China (the "PRC") Government subsidies income received by the Group in the 2020 Interim Period compared to the six months ended 30 June 2019. The increase in Government subsidies mainly consisted of the amounts received from relevant PRC authorities to reward the Group's industrial investment in Guizhou province, and tax rebates subsidy.